GHRP-1 vs GHRP-6.

GHRP-1 is a synthetic heptapeptide, one of the earliest growth hormone-releasing peptides (GHRPs) developed by Cyril Bowers' group in the 1980s and 1990s alongside GHRP-2 and GHRP-6. It is a growth hormone secretagogue, meaning it prompts the pituitary to release the body's own GH rather than being a form of GH itself. It predates the discovery of ghrelin and was one of the pharmacological tools that led researchers to the growth hormone secretagogue receptor (GHS-R1a). It has always been a research compound and was never developed into an approved drug.

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. First described by endocrinologist Cyril Y. Bowers and colleagues in the mid-1980s, it was the prototype of the growth hormone secretagogue (GHS) class and the chemical ancestor of later peptides such as GHRP-2, hexarelin, and ipamorelin. It is not a hormone replacement; rather, it provokes the body's own pituitary to release growth hormone.

GHRP-1 acts as an agonist at GHS-R1a, the receptor later identified as the endogenous ghrelin receptor, which is expressed in the pituitary and hypothalamus. This is a pathway distinct from growth hormone-releasing hormone (GHRH); GHRPs raise GH through a dual action on somatotrophs and on hypothalamic somatostatin and GHRH tone. Because GHRPs were synthesized before ghrelin was identified in 1999, they are best understood as synthetic ghrelin-mimetic secretagogues. The acute receptor mechanism is well characterized in animals and in short human pituitary-response studies.

GHRP-6 is a synthetic agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the G-protein-coupled receptor cloned in 1996 whose endogenous ligand, ghrelin, was identified in 1999. Receptor activation drives phospholipase C signaling, raising inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium and activating protein kinase C, which triggers GH release from somatotrophs. This pathway is distinct from and synergistic with GHRH (which signals through cAMP/PKA), and GHRP-6 also acts on the hypothalamus to amplify GHRH tone and suppress somatostatin. Separately, GHRP-6 binds the scavenger receptor CD36, which is implicated in its proposed cytoprotective and anti-ischemic effects independent of GH release. It also stimulates appetite (via NPY/AgRP arcuate neurons) and can transiently raise cortisol and prolactin.

The GH-releasing activity of GHRP-1 in humans was documented early. Laron, Bowers and colleagues reported in Acta Endocrinologica (1993, PMID 8279223) that intravenous GHRP-1 produced dose-related rises in plasma GH in children and adolescents. That study was an acute endocrine-challenge design: small numbers of participants, single administrations, GH sampled over a few hours, no placebo comparison and no blinding, and no follow-up beyond the sampling window. It answers one question, whether the pituitary responds, and no others. Bowers' wider body of work defined the GHRP class and its combined pituitary and hypothalamic actions, showing that GHRPs act through a receptor separate from the GHRH receptor and that the two stimuli are synergistic when given together. Those experiments formed the pharmacological trail that led to the cloning of GHS-R1a and then to the identification of ghrelin as its natural ligand in 1999 (PMID 10604470). GHRP-1 specifically has far less human data than its siblings GHRP-2 and GHRP-6, and most of its literature consists of acute endocrine-response and animal experiments. GHRP-2 and GHRP-6 accumulated repeat-administration studies, diagnostic use in the assessment of GH deficiency, and observations on appetite and body composition. Ipamorelin, developed later in the same class, was characterized as a more selective secretagogue that raises GH with less accompanying cortisol and prolactin release (PMID 9849822). Nothing comparable exists for GHRP-1, which was largely bypassed once its siblings and then ghrelin itself became the preferred research tools. What is not known is most of it. There are no controlled trials of chronic GHRP-1 use, body composition, or clinical outcomes. There is no published human pharmacokinetic profile for the compound as it is sold, no bioavailability data for routes other than the intravenous administration used in the original studies, no dose-response work extending past the acute GH peak, and no evidence on whether pituitary responsiveness is sustained or subject to tachyphylaxis with repeated exposure. The evidence amounts to proof of mechanism rather than proof of benefit.

In humans, the best-established data are pharmacological/diagnostic: GHRP-6 reliably and synergistically stimulates GH secretion (especially combined with GHRH) and was studied as a GH-provocative agent and probe of the somatotropic axis in the 1990s. Beyond GH provocation, the much-publicized cytoprotective, cardioprotective, and wound/scar-reducing claims rest almost entirely on preclinical work: rodent myocardial infarction and reperfusion models, a rat/rabbit wound and hypertrophic-scar study (Plastic Surgery International, 2016, animal-only), and doxorubicin-cardiotoxicity models. A Clinical Science (2006) paper proposed GHRP-6 for prevention of multiple organ failure, but this remained largely conceptual/preclinical. There are no large, completed, peer-reviewed randomized human trials demonstrating clinical benefit for cardioprotection, healing, or body composition; the human-versus-animal gap here is wide and should not be glossed over.

Acute administration in the early studies was generally tolerated, but there is no long-term human safety data for GHRP-1. As a GH secretagogue it carries the same theoretical concerns as sustained GH elevation, including insulin resistance and fluid retention, and some GHRPs also raise cortisol and prolactin. Those class effects are documented rather than hypothetical: GHRP-2 and GHRP-6 both stimulate ACTH and cortisol release to a degree that ipamorelin was specifically engineered to avoid, and GHRP-6 is a strong appetite stimulant acting through the same ghrelin receptor. Where GHRP-1 sits on that spectrum has never been mapped in a dedicated human study. The recognized consequences of prolonged growth hormone excess, drawn from acromegaly and from supraphysiological GH use, include carpal tunnel symptoms, arthralgia, peripheral edema, worsened glucose tolerance, and cardiac hypertrophy. None of these have been studied for GHRP-1, because no chronic exposure trial exists. Formal toxicology and carcinogenicity packages for the compound are not present in the public literature, and immunogenicity has not been assessed. A legitimate trial would require serial IGF-1 measurement, fasting glucose and insulin or an oral glucose tolerance test, cortisol and prolactin monitoring, thyroid function testing, and periodic assessment for fluid retention and joint symptoms. None of that monitoring occurs outside a clinical setting. Product sold online as GHRP-1 is unregulated research-grade material of uncertain identity and purity, so a vial may contain a different secretagogue, a degraded or truncated peptide, or residual endotoxin and synthesis solvents, and independent testing of the grey peptide market has repeatedly found mislabeled contents. Its human safety profile is largely uncharacterized.

Documented effects in human GH-testing studies include marked stimulation of appetite and transient, usually modest, increases in cortisol and prolactin alongside the intended GH rise, reflecting limited receptor selectivity compared with newer agents like ipamorelin. Because GHS-R1a agonism raises GH and downstream IGF-1, theoretical concerns include fluid retention, insulin resistance/altered glucose handling, and the general caution that sustained GH/IGF-1 elevation could promote growth of existing tumors; these long-term risks are not well characterized for GHRP-6 specifically. There are no robust long-term human safety data, no established safety in pregnancy, and product purity/identity is a major real-world hazard since material sold for "research" is unregulated. No dosing or administration guidance is provided here.

GHRP-1 has never been approved by the FDA or any major regulator for any indication. It is a research chemical sold only for laboratory use. As a growth hormone secretagogue it is prohibited in sport by WADA.

GHRP-6 is not approved by the FDA (or other major regulators) for any therapeutic indication and is an investigational/research-use-only compound. As a growth hormone secretagogue, it falls under substances prohibited in sport at all times by the World Anti-Doping Agency (WADA).